AACR 2023 | Intratumoral MEDI1191 encoding IL-12 in solid tumors

Omid Hamid, MD, The Angeles Clinic and Research Institute, Los Angeles, CA, provides an overview of the Phase I trial (NCT03946800) assessing MEDI1191, an injectable lipid nanoparticle-formulated therapy containing mRNA encoding IL-12. Whilst there were responses in terms of activation of the immune system, especially in patients with melanoma, the primary endpoint was not met. This interview took place at the American Association for Cancer Research (AACR) Annual Meeting 2023 in Orlando, FL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.